59.66 USD
+1.85 (+3.2%)
At close: Feb 10, 2026
59.66 USD
0 (0%)
After Hours: 2/10/2026, 8:00:02 PM
Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 523 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year BMRN was profitable.
- BMRN had a positive operating cash flow in the past year.
- Of the past 5 years BMRN 4 years were profitable.
- Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
- BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.54% of its industry peers.
- BMRN has a Return On Equity of 8.59%. This is amongst the best in the industry. BMRN outperforms 91.97% of its industry peers.
- BMRN has a better Return On Invested Capital (7.69%) than 93.88% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.27%.
- The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 16.82%, BMRN belongs to the top of the industry, outperforming 92.54% of the companies in the same industry.
- BMRN's Operating Margin of 20.21% is amongst the best of the industry. BMRN outperforms 94.46% of its industry peers.
- BMRN has a Gross Margin of 81.32%. This is amongst the best in the industry. BMRN outperforms 85.28% of its industry peers.
- In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
- The number of shares outstanding for BMRN has been increased compared to 1 year ago.
- BMRN has more shares outstanding than it did 5 years ago.
- BMRN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.61 indicates that BMRN is not in any danger for bankruptcy at the moment.
- BMRN has a better Altman-Z score (5.61) than 73.81% of its industry peers.
- BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
- The Debt to FCF ratio of BMRN (0.72) is better than 94.46% of its industry peers.
- A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
- BMRN has a worse Debt to Equity ratio (0.10) than 62.33% of its industry peers.
- Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.61 |
ROIC/WACC0.63
WACC12.13%
2.3 Liquidity
- BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
- BMRN has a Current ratio (4.83) which is comparable to the rest of the industry.
- A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.10, BMRN is doing worse than 60.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
- The Revenue has grown by 12.39% in the past year. This is quite good.
- BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.19% yearly.
- The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 22.43, which indicates a rather expensive current valuation of BMRN.
- Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.46% of the companies in the same industry.
- BMRN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.03, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 13.46, the valuation of BMRN can be described as correct.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 96.75% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (27.97), we can say BMRN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.43 | ||
| Fwd PE | 13.46 |
4.2 Price Multiples
- 95.41% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
- BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.88 | ||
| EV/EBITDA | 14.62 |
4.3 Compensation for Growth
- BMRN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BMRN has a very decent profitability rating, which may justify a higher PE ratio.
- BMRN's earnings are expected to grow with 34.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y41.64%
EPS Next 3Y34.83%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
59.66
+1.85 (+3.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners97.82%
Inst Owner Change-2.63%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.46B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target94.32 (58.1%)
Short Float %3.88%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)2.44%
PT rev (3m)-1.45%
EPS NQ rev (1m)-32.68%
EPS NQ rev (3m)-35.34%
EPS NY rev (1m)-10.07%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.43 | ||
| Fwd PE | 13.46 | ||
| P/S | 3.7 | ||
| P/FCF | 13.88 | ||
| P/OCF | 12.54 | ||
| P/B | 1.89 | ||
| P/tB | 2.04 | ||
| EV/EBITDA | 14.62 |
EPS(TTM)2.66
EY4.46%
EPS(NY)4.43
Fwd EY7.43%
FCF(TTM)4.3
FCFY7.21%
OCF(TTM)4.76
OCFY7.97%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)1.02
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.61 |
F-Score8
WACC12.13%
ROIC/WACC0.63
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 22.03% in the next year.